

35504/21.10.15

GOVERNMENT OF INDIA

Directorate General of Health Services
Central Drugs Standard Control Organization
Office of Drugs Controller General (India)

(Global Clinical Trial Division)

FDA Bhawan, Kotla Road, New Delhi-110002
Tel No: 01123236965, Fax: 01123236971
E-mail: dci@nic.in

File No: CT/46/15 – DCG (I)

Date: 08/08/16

To,

M/s AstraZeneca Pharma India Limited,
Block N1, 12th Floor, Manyata Embassy Business Park,
Rachenahalli, Outer Ring Road Bangalore-560045

Subject: Permission for conducting clinical trial titled “A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 in Combination with Tremelimumab Therapy Versus Standard of Care Platinum-Based Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) (NEPTUNE).” – regarding.

Reference: - Your letter No. REG/2015/CT/DGHS/053 dated 20th Oct 2015 on the subject mentioned above
Sir,

This Directorate has no objection to your conducting the subject mentioned clinical trial as per the provisions of Drugs & Cosmetics Rules under supervision of the following investigators and as per the Protocol No: D419AC00003, Local Amendment No. 1, Edition No. 01, dated 21/March/2016 submitted to this Directorate.

1. Dr. Shyam Aggarwal, Dept. of Medical Oncology, Sir Ganga Ram Hospital, Rajinder Nagar, New Delhi-110060.
2. Dr. Ashish Singh, Department of Medical Oncology, Christian Medical College, Ida Scudder Road, Vellore - 632004, Tamil Nadu.
3. Dr. K. Pavithran, Amrita Institute of Medical Sciences and Research Centre, Ponakkara P.O., Cochin - 682041, Kerala.
4. Dr. Hemant Malhotra, R K Birla Cancer Centre, SMS Medical College Hospital, Jaipur - 302001, Rajasthan.
5. Dr. Shekar Gowda Patil, Health Care Global Enterprises Limited, HCG Towers, #8, P. Kalinga Rao Road, Sampangi Ram Nagar, Bangalore - 560027, Karnataka.
6. Dr. Balasubramaniam Sivanesan, G. Kuppuswamy Naidu Memorial Hospital, Post Box No. 6327, Nethaji Road, P.N. Palayam, Coimbatore - 641037, Tamil Nadu.
7. Dr. Harsha .P. Panchal, The Gujarat Cancer & Research Institute, M.P Shah Cancer Hospital, New Civil Hospital Campus, Asarwa, Ahmedabad, - 380016, Gujarat.
8. Dr. Krishnakumar Rathnam, Meenakshi Mission Hospital and Research Centre, Lake Area, Melur Road, Madurai - 625107, Tamil Nadu.
9. Dr. Sachin Vamanrao Almel, Dept. of Oncology, P.D.Hinduja National Hospital & Medical Research Centre, Ground Floor, Wing No 1, OPD Building, Room No 106, Veer Savarkar Marg, Mahim West, Mumbai - 400016, Maharashtra.
10. Dr. Dinesh Chandra Doval, Rajiv Gandhi Cancer Institute and Research Centre, Sector-V, Rohini, New Delhi – 110085.

11. Dr. Sankar Srinivasan, Apollo Speciality Hospital, Padma Complex, No. 320, Anna Salai, Chennai -600035, Tamil Nadu, India.


12. Dr. Sushant Mittal, Artemis Hospital, Sector-51, Gurgaon-12200, Haryana.

Kindly note that the clinical trial permission is subject to the following conditions:

- a. **A system of instant electronic communication between subjects and study site should be in place to ensure prompt adverse event reporting and management.**
- b. Clinical trial shall be conducted in compliance with the approved protocols, requirements of Schedule Y, Good Clinical Practice Guidelines issued by this Directorate and other applicable regulations.
- c. Approval of the Ethics Committee shall be obtained before initiation of the study.
- d. Clinical trials shall be registered at Clinical trials Registry of India before enrolling the first patient for the study.
- e. Annual status report of each clinical trial, as to whether it is ongoing, completed or terminated, shall be submitted to the Licensing Authority, and in case of termination of any clinical trial the detailed reasons for the same shall be communicated to the said Licensing Authority.
- f. Any report of serious adverse event occurring during clinical trial study to the subject, after due analysis, shall be forwarded within fourteen days of its occurrence as per Appendix XI and in compliance with the procedures prescribed in Schedule Y.
- g. In case of an injury or death during the study to the subjects, the applicant shall provide complete medical management and compensation in the case of trial related injury or death in accordance with rule 122 DAB and the procedures prescribed under Schedule Y, and the details of compensation provided in such cases shall be intimated to the Licensing Authority within thirty days of the receipt of the order of the said authority.
- h. The premises of Sponsor including their employees, subsidiaries and branches, their agents, contractors and sub-contractors and clinical trial study sites shall be open to inspection by the officers authorized by the Central Drugs Standard Control Organization, who may be accompanied by an officer of the State Drug Control Authority concerned, to verify compliance to the requirements of Schedule Y, Good Clinical Practices guidelines for conduct of clinical trial in India and other applicable regulations.
- i. The Sponsor including their employees, subsidiaries and branches, their agents, contractors and sub-contractors and clinical trial study sites and the Investigator shall allow officers authorized by the Central Drugs Standard Control Organization, who may be accompanied by an officer of the State Drug Control Authority concerned, to enter with or without prior notice, any premises of Sponsor including their employees, subsidiaries and branches, their agents, contractors and sub-contractors and clinical trial sites to inspect, search and seize any record, data, document, books, investigational drugs, etc. related to clinical trial and provide adequate replies to any queries raised by the inspecting authority in relation to the conduct of clinical trial.
- j. Clinical trial shall be conducted only at those sites which are institutes/hospitals having adequate emergency facilities and duly registered Institutional Ethics committees.
- k. The sponsor shall ensure that the number of clinical trials an investigator can undertake should be commensurate with the nature of the trial, facility available with the Investigator etc. However, under no circumstances the number of trials should be more than three at a time.
- l. The details of payment/honorarium/financial support/fees paid by the Sponsor to the Investigator(s) for conducting the study shall be made available to this directorate before initiation of each of the trial sites.

- m. An audio-video recording of the informed consent process in case of vulnerable subjects in clinical trials of New Chemical Entity or New Molecular Entity including procedure of providing information to the subject and his understanding on such consent, shall be maintained by the investigator for record. Provided that in case of clinical trial of anti-HIV and anti-Leprosy drugs, only audio recording of the informed consent process of individual subject including the procedure of providing information to the subject and his understanding on such consent shall be maintained by the investigator for record.
- n. It may kindly be noted that merely granting permission to conduct clinical trials with the drug does not convey or imply that based on the clinical trial data generated with the drug, permission to market this drug in the country will automatically be granted to you.

Yours faithfully,



(Dr. G.N. Singh)
Drugs Controller General (I)

